Serotype-independent pneumococcal vaccines

Cellular and Molecular Life Sciences

Volumn 70, Issue 18, 2013, Pages 3303-3326

  Miyaji, Eliane Namie ^a   Oliveira, Maria Leonor Sarno ^a   Carvalho, Eneas ^a   Ho, Paulo Lee ^a  

^a INSTITUTO BUTANTAN   (Brazil)

Author keywords

Streptococcus pneumoniae; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIAL VACCINE; BACTERIAL VECTOR; CD4 ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; GAMMA INTERFERON; IC 47; INTERLEUKIN 17; INTERLEUKIN 8; PEPTIDOGLYCAN; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; PROPIOLACTONE; PROTEIN PSAA; PROTEIN PSPA; PROTEIN PSPC; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIGEN EXPRESSION; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CD4+ T LYMPHOCYTE; GENE DELIVERY SYSTEM; HUMAN; LACTIC ACID BACTERIUM; MUCOSAL DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMOCOCCAL INFECTION; REVIEW; SEROTYPE; TH17 CELL;

ANIMALS; ANTIGENS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MENINGITIS, BACTERIAL; MICE; MUCOUS MEMBRANE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RECOMBINANT PROTEINS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

ANIMALIA; STREPTOCOCCUS PNEUMONIAE;

EID: 84883452514     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-012-1234-8     Document Type: Review

References (175)

1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374(9693):893-902. doi: 10.1016/S0140-6736(09)61204-6
2. Calix JJ, Porambo RJ, Brady AM, Larson TR, Yother J, Abeygunwardana C, Nahm MH (2012) Biochemical, genetic, and serological characterization of two capsule subtypes among streptococcus pneumoniae serotype 20 strains: discovery of a new pneumococcal serotype. J Biol Chem 287(33):27885-27894. doi: 10.1074/jbc.M112.380451
3. Calix JJ, Nahm MH (2010) A new pneumococcal serotype, 11E, has a variably inactivated wcjE gene. J Infect Dis 202(1):29-38. doi: 10.1086/653123
4. Jin P, Kong F, Xiao M, Oftadeh S, Zhou F, Liu C, Russell F, Gilbert GL (2009) First report of putative Streptococcus pneumoniae serotype 6D among nasopharyngeal isolates from Fijian children. J Infect Dis 200(9):1375-1380. doi: 10.1086/606118
5. Park IH, Park S, Hollingshead SK, Nahm MH (2007) Genetic basis for the new pneumococcal serotype, 6C. Infect Immun 75(9):4482-4489. doi: 10.1128/IAI.00510-07
6. JCVI (Joint Committee on Vaccination and Immunisation) (2011) JCVI [Joint Committee on Vaccination and Immunisation] statement on discontinuation of the routine pneumococcal vaccination programme for adults aged 65 years and older, 2012 (02/10/2012)
7. Trotter CL, Waight P, Andrews NJ, Slack M, Efstratiou A, George R, Miller E (2010) Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996-2006. J Infect 60(3):200-208. doi: 10.1016/j.jinf.2009.12.008
8. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348(18):1737-1746. doi: 10.1056/NEJMoa022823
9. Ghaffar F, Barton T, Lozano J, Muniz LS, Hicks P, Gan V, Ahmad N, McCracken GH Jr (2004) Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 39(7):930-938
10. Pelton SI, Loughlin AM, Marchant CD (2004) Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 23(11):1015-1022
11. Moffitt KL, Gierahn TM, Lu YJ, Gouveia P, Alderson M, Flechtner JB, Higgins DE, Malley R (2011) T(H)17-based vaccine design for prevention of streptococcus pneumoniae colonization. Cell Host Microbe 9(2):158-165. doi: 10.1016/j.chom.2011.01.007
12. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297(16):1784-1792. doi: 10.1001/jama.297.16.1784
13. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, Reingold A, Farley MM, Whitney CG (2007) Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 196(9):1346-1354. doi: 10.1086/521626
14. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, Farley MM, Jorgensen JH, Lexau CA, Petit S, Reingold A, Schaffner W, Thomas A, Whitney CG, Harrison LH (2009) Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 360(3):244-256. doi: 10.1056/NEJMoa0800836
15. Kaplan SL, Mason EO Jr, Wald ER, Schutze GE, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Yogev R, Barson WJ (2004) Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113(3 Pt 1):443-449
16. Frazao N, Brito-Avo A, Simas C, Saldanha J, Mato R, Nunes S, Sousa NG, Carrico JA, Almeida JS, Santos-Sanches I, de Lencastre H (2005) Effect of the seven-valent conjugate pneumococcal vaccine on carriage and drug resistance of Streptococcus pneumoniae in healthy children attending day-care centers in Lisbon. Pediatr Infect Dis J 24(3):243-252 (pii: 00006454-200503000-00010)
17. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA (2005) Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116(3):e408-e413. doi: 10.1542/peds.2004-2338
18. CDC (Centers for Disease Control and Prevention) (2010) Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine, United States, 2007. MMWR morbidity and mortality weekly report, vol 59, Atlanta, GA
19. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201(1):32-41. doi: 10.1086/648593
20. Weinberger DM, Malley R, Lipsitch M (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 378(9807):1962-1973. doi: 10.1016/S0140-6736(10)62225-8
21. Gladstone RA, Jefferies JM, Faust SN, Clarke SC (2011) Continued control of pneumococcal disease in the UK: the impact of vaccination. J Med Microbiol 60(Pt 1):1-8. doi: 10.1099/jmm.0.020016-0
22. Levy C, Varon E, Bingen E, Lecuyer A, Boucherat M, Cohen R (2011) PneumococcaL meningitis in french children before and after the introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 30(2):168-170
23. Bogaert D, De Groot R, Hermans PW (2004) Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4(3):144-154
24. Hill PC, Cheung YB, Akisanya A, Sankareh K, Lahai G, Greenwood BM, Adegbola RA (2008) Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: a longitudinal study. Clin Infect Dis 46(6):807-814. doi: 10.1086/528688
25. Ghaffar F, Friedland IR, McCracken GH Jr (1999) Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr Infect Dis J 18(7):638-646
26. Musher DM, Alexandraki I, Graviss EA, Yanbeiy N, Eid A, Inderias LA, Phan HM, Solomon E (2000) Bacteremic and nonbacteremic pneumococcal pneumonia: aA prospective study. Medicine 79(4):210-221
27. Brandenburg JA, Marrie TJ, Coley CM, Singer DE, Obrosky DS, Kapoor WN, Fine MJ (2000) Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. J Gen Intern Med 15(9):638-646
28. Weiser JN, Austrian R, Sreenivasan PK, Masure HR (1994) Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect Immun 62(6):2582-2589
29. Kim JO, Weiser JN (1998) Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J Infect Dis 177(2):368-377
30. Dalia AB, Weiser JN (2011) Minimization of bacterial size allows for complement evasion and is overcome by the agglutinating effect of antibody. Cell Host Microbe 10(5):486-496. doi: 10.1016/j.chom.2011.09.009
31. Rodriguez JL, Dalia AB, Weiser JN (2012) Increased chain length promotes pneumococcal adherence and colonization. Infect Immun 80(10):3454-3459. doi: 10.1128/IAI.00587-12
32. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19(3):187-195
33. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Kayhty H, Karma P, Kohberger R, Siber G, Makela PH (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344(6):403-409. doi: 10.1056/NEJM200102083440602
34. Madhi SA, Whitney CG, Nohynek H (2008) Lessons learned from clinical trials evaluating pneumococcal conjugate vaccine efficacy against pneumonia and invasive disease. Vaccine 26(Suppl 2):B9-B15. doi: 10.1016/j.vaccine.2008.06.001
35. Rose CE, Romero-Steiner S, Burton RL, Carlone GM, Goldblatt D, Nahm MH, Ashton L, Haston M, Ekstrom N, Haikala R, Kayhty H, Henckaerts I, Durant N, Poolman JT, Fernsten P, Yu X, Hu BT, Jansen KU, Blake M, Simonetti ER, Hermans PW, Plikaytis BD (2011) Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. Clin Vaccine Immunol 18(1):135-142. doi: 10.1128/CVI.00370-10
36. Lipsitch M, Whitney CG, Zell E, Kaijalainen T, Dagan R, Malley R (2005) Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med 2(1):e15. doi: 10.1371/journal.pmed.0020015
37. Rapola S, Jantti V, Haikala R, Syrjanen R, Carlone GM, Sampson JS, Briles DE, Paton JC, Takala AK, Kilpi TM, Kayhty H (2000) Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis 182(4):1146-1152
38. Laine C, Mwangi T, Thompson CM, Obiero J, Lipsitch M, Scott JA (2004) Age-specific immunoglobulin g (IgG) and IgA to pneumococcal protein antigens in a population in coastal kenya. Infect Immun 72(6):3331-3335
39. McCool TL, Cate TR, Moy G, Weiser JN (2002) The immune response to pneumococcal proteins during experimental human carriage. J Exp Med 195(3):359-365
40. Briles DE, Forman C, Crain M (1992) Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniae. Infect Immun 60(5):1957-1962
41. Goldenberg HB, McCool TL, Weiser JN (2004) Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract. J Infect Dis 190(7):1254-1263. doi: 10.1086/424517
42. Simell B, Korkeila M, Pursiainen H, Kilpi TM, Kayhty H (2001) Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal surface adhesin a, pneumolysin, and pneumococcal surface protein a in children. J Infect Dis 183(6):887-896
43. Simell B, Kilpi TM, Kayhty H (2002) Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal capsular polysaccharides in children. J Infect Dis 186(8):1106-1114. doi: 10.1086/344235
44. Fukuyama Y, King JD, Kataoka K, Kobayashi R, Gilbert RS, Oishi K, Hollingshead SK, Briles DE, Fujihashi K (2010) Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae. J Immunol 185(3):1755-1762. doi: 10.4049/jimmunol.1000831
45. Briles DE, Miyaji E, Fukuyama Y, Ferreira DM, Fujihashi K (2011) Elicitation of mucosal immunity by proteins of Streptococcus pneumoniae. Adv Otorhinolaryngol 72:25-27. doi: 10.1159/000324589
46. Ferreira DM, Oliveira ML, Moreno AT, Ho PL, Briles DE, Miyaji EN (2010) Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A). Microb Pathog 48(6):205-213. doi: 10.1016/j.micpath.2010.02.009
47. McCool TL, Weiser JN (2004) Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization. Infect Immun 72(10):5807-5813
48. Trzcinski K, Thompson C, Malley R, Lipsitch M (2005) Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model. Infect Immun 73(10):7043-7046
49. Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, Lipsitch M (2005) CD4 + T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 102(13):4848-4853
50. Lu YJ, Gross J, Bogaert D, Finn A, Bagrade L, Zhang Q, Kolls JK, Srivastava A, Lundgren A, Forte S, Thompson CM, Harney KF, Anderson PW, Lipsitch M, Malley R (2008) Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 4(9):e1000159. doi: 10.1371/journal.ppat.1000159
51. Zhang Z, Clarke TB, Weiser JN (2009) Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 119(7):1899-1909. doi: 10.1172/JCI36731
52. Jambo KC, Sepako E, Heyderman RS, Gordon SB (2010) Potential role for mucosally active vaccines against pneumococcal pneumonia. Trends Microbiol 18(2):81-89. doi: 10.1016/j.tim.2009.12.001
53. Veenhoven R, Bogaert D, Uiterwaal C, Brouwer C, Kiezebrink H, Bruin J, E IJ, Hermans P, de Groot R, Zegers B, Kuis W, Rijkers G, Schilder A, Sanders E (2003) Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 361(9376):2189-2195
54. Spijkerman J, Prevaes SM, van Gils EJ, Veenhoven RH, Bruin JP, Bogaert D, Wijmenga-Monsuur AJ, van den Dobbelsteen GP, Sanders EA (2012) Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PLoS ONE 7(6):e39730. doi: 10.1371/journal.pone.0039730
55. Kilian M, Mestecky J, Kulhavy R, Tomana M, Butler WT (1980) IgA1 proteases from Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, and Streptococcus sanguis: comparative immunochemical studies. J Immunol 124(6):2596-2600
56. Chiavolini D, Pozzi G, Ricci S (2008) Animal models of Streptococcus pneumoniae disease. Clin Microbiol Rev 21(4):666-685. doi: 10.1128/CMR.00012-08
57. Briles DE, Hollingshead SK, Jondottir I (2008) Animal models of invasive pneumococcal disease. In: Siber GR, Klugman KP, Makela PH (eds) Pneumococcal vaccines: the impact of conjugate vaccine. ASM Press, Washington, pp 47-58
58. Malley R, Weiser JN (2008) Animal models of pneumococcal colonization. In: Siber GR, Klugman KP, Makela PH (eds) Pneumococcal vaccines: the impact of conjugate vaccine. ASM Press, Washington, pp 59-66
59. Kerner JD, Appleby MW, Mohr RN, Chien S, Rawlings DJ, Maliszewski CR, Witte ON, Perlmutter RM (1995) Impaired expansion of mouse B cell progenitors lacking Btk. Immunity 3(3):301-312
60. Briles DE, Nahm M, Schroer K, Davie J, Baker P, Kearney J, Barletta R (1981) Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J Exp Med 153(3):694-705
61. Jakobsen H, Bjarnarson S, Del Giudice G, Moreau M, Siegrist CA, Jonsdottir I (2002) Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect Immun 70(3):1443-1452
62. Jakobsen H, Hannesdottir S, Bjarnarson SP, Schulz D, Trannoy E, Siegrist CA, Jonsdottir I (2006) Early life T cell responses to pneumococcal conjugates increase with age and determine the polysaccharide-specific antibody response and protective efficacy. Eur J Immunol 36(2):287-295. doi: 10.1002/eji.200535102
63. Briles DE, Crain MJ, Gray BM, Forman C, Yother J (1992) Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun 60(1):111-116
64. Briles DE, Novak L, Hotomi M, van Ginkel FW, King J (2005) Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococci. Infect Immun 73(10):6945-6951
65. Briles DE, Hollingshead SK, Paton JC, Ades EW, Novak L, van Ginkel FW, Benjamin WH Jr (2003) Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 188(3):339-348
66. Takashima K, Tateda K, Matsumoto T, Ito T, Iizawa Y, Nakao M, Yamaguchi K (1996) Establishment of a model of penicillin-resistant Streptococcus pneumoniae pneumonia in healthy CBA/J mice. J Med Microbiol 45(5):319-322
67. Philipp MT, Purcell JE, Martin DS, Buck WR, Plauche GB, Ribka EP, DeNoel P, Hermand P, Leiva LE, Bagby GJ, Nelson S (2006) Experimental infection of rhesus macaques with Streptococcus pneumoniae: a possible model for vaccine assessment. J Med Primatol 35(3):113-122. doi: 10.1111/j.1600-0684.2006.00164.x
68. Giebink GS (1999) Otitis media: the chinchilla model. Microb Drug Resist 5(1):57-72
69. Sabirov A, Metzger DW (2008) Mouse models for the study of mucosal vaccination against otitis media. Vaccine 26(12):1501-1524. doi: 10.1016/j.vaccine.2008.01.029
70. Zhang Q, Choo S, Finn A (2002) Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children. Infect Immun 70(10):5363-5369
71. Perez-Dorado I, Galan-Bartual S, Hermoso JA (2012) Pneumococcal surface proteins: when the whole is greater than the sum of its parts. Molecular Oral Microbiol 27(4):221-245. doi: 10.1111/j.2041-1014.2012.00655.x
72. Gamez G, Hammerschmidt S (2012) Combat pneumococcal infections: adhesins as candidates for protein-based vaccine development. Curr Drug Targets 13(3):323-337
73. Sham LT, Barendt SM, Kopecky KE, Winkler ME (2011) Essential PcsB putative peptidoglycan hydrolase interacts with the essential FtsXSpn cell division protein in Streptococcus pneumoniae D39. Proc Natl Acad Sci USA 108(45):E1061-E1069. doi: 10.1073/pnas.1108323108
74. Rossjohn J, Gilbert RJ, Crane D, Morgan PJ, Mitchell TJ, Rowe AJ, Andrew PW, Paton JC, Tweten RK, Parker MW (1998) The molecular mechanism of pneumolysin, a virulence factor from Streptococcus pneumoniae. J Mol Biol 284(2):449-461. doi: 10.1006/jmbi.1998.2167
75. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, Thompson CM, Kurt-Jones E, Paton JC, Wessels MR, Golenbock DT (2003) Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 100(4):1966-1971. doi: 10.1073/pnas.0435928100
76. McNeela EA, Burke A, Neill DR, Baxter C, Fernandes VE, Ferreira D, Smeaton S, El-Rachkidy R, McLoughlin RM, Mori A, Moran B, Fitzgerald KA, Tschopp J, Petrilli V, Andrew PW, Kadioglu A, Lavelle EC (2010) Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog 6(11):e1001191. doi: 10.1371/journal.ppat.1001191
77. Witzenrath M, Pache F, Lorenz D, Koppe U, Gutbier B, Tabeling C, Reppe K, Meixenberger K, Dorhoi A, Ma J, Holmes A, Trendelenburg G, Heimesaat MM, Bereswill S, van der Linden M, Tschopp J, Mitchell TJ, Suttorp N, Opitz B (2011) The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J Immunol 187(1):434-440. doi: 10.4049/jimmunol.1003143
78. Paton JC, Lock RA, Hansman DJ (1983) Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun 40(2):548-552
79. Lock RA, Hansman D, Paton JC (1992) Comparative efficacy of autolysin and pneumolysin as immunogens protecting mice against infection by Streptococcus pneumoniae. Microb Pathog 12(2):137-143
80. Alexander JE, Lock RA, Peeters CC, Poolman JT, Andrew PW, Mitchell TJ, Hansman D, Paton JC (1994) Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 62(12):5683-5688
81. McDaniel LS, Scott G, Kearney JF, Briles DE (1984) Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med 160(2):386-397
82. McDaniel LS, Scott G, Widenhofer K, Carroll JM, Briles DE (1986) Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodies. Microb Pathog 1(6):519-531
83. Yother J, Briles DE (1992) Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J Bacteriol 174(2):601-609
84. Ren B, McCrory MA, Pass C, Bullard DC, Ballantyne CM, Xu Y, Briles DE, Szalai AJ (2004) The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection. J Immunol 173(12):7506-7512 (pii: 173/12/7506)
85. Tu AH, Fulgham RL, McCrory MA, Briles DE, Szalai AJ (1999) Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun 67(9):4720-4724
86. Shaper M, Hollingshead SK, Benjamin WH Jr, Briles DE (2004) PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun 72(9):5031-5040
87. Hollingshead SK, Becker R, Briles DE (2000) Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 68(10):5889-5900
88. Vela Coral MC, Fonseca N, Castaneda E, Di Fabio JL, Hollingshead JK, Briles DE (2001) Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children. Emerg Infect Dis 7(5):832-836
89. Brandileone MC, Andrade AL, Teles EM, Zanella RC, Yara TI, Di Fabio JL, Hollingshead SK (2004) Typing of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolated during epidemiological surveillance in Brazil: towards novel pneumococcal protein vaccines. Vaccine 22(29-30):3890-3896
90. Tart RC, McDaniel LS, Ralph BA, Briles DE (1996) Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis 173(2):380-386
91. Moreno AT, Oliveira ML, Ferreira DM, Ho PL, Darrieux M, Leite LC, Ferreira JM Jr, Pimenta FC, Andrade AL, Miyaji EN (2010) Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol 17(3):439-446. doi: 10.1128/CVI.00430-09
92. McDaniel LS, Sheffield JS, Delucchi P, Briles DE (1991) PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun 59(1):222-228
93. McDaniel LS, Ralph BA, McDaniel DO, Briles DE (1994) Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog 17(5):323-337
94. Briles DE, King JD, Gray MA, McDaniel LS, Swiatlo E, Benton KA (1996) PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine 14(9):858-867 (pii: 0264410X96829483)
95. Wu HY, Nahm MH, Guo Y, Russell MW, Briles DE (1997) Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 175(4):839-846
96. Melin M, Coan P, Hollingshead S (2012) Development of cross-reactive antibodies to the proline-rich region of pneumococcal surface protein A in children. Vaccine. doi: 10.1016/j.vaccine.2012.10.004
97. Daniels CC, Coan P, King J, Hale J, Benton KA, Briles DE, Hollingshead SK (2010) The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun 78(5):2163-2172. doi: 10.1128/IAI.01199-09
98. Russell H, Tharpe JA, Wells DE, White EH, Johnson JE (1990) Monoclonal antibody recognizing a species-specific protein from Streptococcus pneumoniae. J Clin Microbiol 28(10):2191-2195
99. Rajam G, Anderton JM, Carlone GM, Sampson JS, Ades EW (2008) Pneumococcal surface adhesin A (PsaA): a review. Crit Rev Microbiol 34(3-4):131-142. doi: 10.1080/10408410802275352
100. Briles DE, Ades E, Paton JC, Sampson JS, Carlone GM, Huebner RC, Virolainen A, Swiatlo E, Hollingshead SK (2000) Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 68(2):796-800
101. Brooks-Walter A, Briles DE, Hollingshead SK (1999) The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun 67(12):6533-6542
102. Rosenow C, Ryan P, Weiser JN, Johnson S, Fontan P, Ortqvist A, Masure HR (1997) Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol 25(5):819-829
103. Hammerschmidt S, Talay SR, Brandtzaeg P, Chhatwal GS (1997) SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol Microbiol 25(6):1113-1124
104. Janulczyk R, Iannelli F, Sjoholm AG, Pozzi G, Bjorck L (2000) Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function. J Biol Chem 275(47):37257-37263
105. Cheng Q, Finkel D, Hostetter MK (2000) Novel purification scheme and functions for a C3-binding protein from Streptococcus pneumoniae. Biochemistry 39(18):5450-5457
106. Dave S, Brooks-Walter A, Pangburn MK, McDaniel LS (2001) PspC, a pneumococcal surface protein, binds human factor H. Infect Immun 69(5):3435-3437
107. Jarva H, Janulczyk R, Hellwage J, Zipfel PF, Bjorck L, Meri S (2002) Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol 168(4):1886-1894
108. Orihuela CJ, Mahdavi J, Thornton J, Mann B, Wooldridge KG, Abouseada N, Oldfield NJ, Self T, Ala'Aldeen DA, Tuomanen EI (2009) Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J Clin Invest 119(6):1638-1646. doi: 10.1172/JCI36759
109. Balachandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollingshead SK, Briles DE (2002) Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun 70(5):2526-2534
110. Ogunniyi AD, Woodrow MC, Poolman JT, Paton JC (2001) Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun 69(10):5997-6003
111. Iannelli F, Oggioni MR, Pozzi G (2002) Allelic variation in the highly polymorphic locus pspC of Streptococcus pneumoniae. Gene 284(1-2):63-71 (pii: S0378111901008964)
112. Moreno AT, Oliveira ML, Ho PL, Vadesilho CF, Palma GM, Ferreira JM Jr, Ferreira DM, Santos SR, Martinez MB, Miyaji EN (2012) Cross-reactivity of antipneumococcal surface protein C (PspC) antibodies with different strains and evaluation of inhibition of human complement factor H and secretory IgA binding via PspC. Clin Vaccine Immunol 19(4):499-507. doi: 10.1128/CVI.05706-11
113. Adamou JE, Heinrichs JH, Erwin AL, Walsh W, Gayle T, Dormitzer M, Dagan R, Brewah YA, Barren P, Lathigra R, Langermann S, Koenig S, Johnson S (2001) Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 69(2):949-958. doi: 10.1128/IAI.69.2.949-958.2001
114. Zhang Y, Masi AW, Barniak V, Mountzouros K, Hostetter MK, Green BA (2001) Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge. Infect Immun 69(6):3827-3836. doi: 10.1128/IAI.69.6.3827-3836.2001
115. Hamel J, Charland N, Pineau I, Ouellet C, Rioux S, Martin D, Brodeur BR (2004) Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun 72(5):2659-2670
116. Godfroid F, Hermand P, Verlant V, Denoel P, Poolman JT (2011) Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun 79(1):238-245. doi: 10.1128/IAI.00378-10
117. Denoel P, Philipp MT, Doyle L, Martin D, Carletti G, Poolman JT (2011) A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 29(33):5495-5501. doi: 10.1016/j.vaccine.2011.05.051
118. Jomaa M, Terry S, Hale C, Jones C, Dougan G, Brown J (2006) Immunization with the iron uptake ABC transporter proteins PiaA and PiuA prevents respiratory infection with Streptococcus pneumoniae. Vaccine 24(24):5133-5139. doi: 10.1016/j.vaccine.2006.04.012
119. Brown JS, Ogunniyi AD, Woodrow MC, Holden DW, Paton JC (2001) Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection. Infect Immun 69(11):6702-6706. doi: 10.1128/IAI.69.11.6702-6706.2001
120. Jomaa M, Yuste J, Paton JC, Jones C, Dougan G, Brown JS (2005) Antibodies to the iron uptake ABC transporter lipoproteins PiaA and PiuA promote opsonophagocytosis of Streptococcus pneumoniae. Infect Immun 73(10):6852-6859. doi: 10.1128/IAI.73.10.6852-6859.2005
121. Harfouche C, Filippini S, Gianfaldoni C, Ruggiero P, Moschioni M, Maccari S, Pancotto L, Arcidiacono L, Galletti B, Censini S, Mori E, Giuliani M, Facciotti C, Cartocci E, Savino S, Doro F, Pallaoro M, Nocadello S, Mancuso G, Haston M, Goldblatt D, Barocchi MA, Pizza M, Rappuoli R, Masignani V (2012) RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. Infect Immun 80(1):451-460. doi: 10.1128/IAI.05780-11
122. Aguiar SI, Serrano I, Pinto FR, Melo-Cristino J, Ramirez M (2008) The presence of the pilus locus is a clonal property among pneumococcal invasive isolates. BMC Microbiol 8:41. doi: 10.1186/1471-2180-8-41
123. Moschioni M, Donati C, Muzzi A, Masignani V, Censini S, Hanage WP, Bishop CJ, Reis JN, Normark S, Henriques-Normark B, Covacci A, Rappuoli R, Barocchi MA (2008) Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related. J Infect Dis 197(6):888-896. doi: 10.1086/528375
124. Bagnoli F, Moschioni M, Donati C, Dimitrovska V, Ferlenghi I, Facciotti C, Muzzi A, Giusti F, Emolo C, Sinisi A, Hilleringmann M, Pansegrau W, Censini S, Rappuoli R, Covacci A, Masignani V, Barocchi MA (2008) A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells. J Bacteriol 190(15):5480-5492. doi: 10.1128/JB.00384-08
125. Basset A, Turner KH, Boush E, Sayeed S, Dove SL, Malley R (2011) Expression of the type 1 pneumococcal pilus is bistable and negatively regulated by the structural component RrgA. Infect Immun 79(8):2974-2983. doi: 10.1128/IAI.05117-11
126. De Angelis G, Moschioni M, Muzzi A, Pezzicoli A, Censini S, Delany I, Lo Sapio M, Sinisi A, Donati C, Masignani V, Barocchi MA (2011) The Streptococcus pneumoniae pilus-1 displays a biphasic expression pattern. PLoS ONE 6(6):e21269. doi: 10.1371/journal.pone.0021269
127. Glover DT, Hollingshead SK, Briles DE (2008) Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun 76(6):2767-2776. doi: 10.1128/IAI.01126-07
128. Ogunniyi AD, Folland RL, Briles DE, Hollingshead SK, Paton JC (2000) Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 68(5):3028-3033
129. Ogunniyi AD, Grabowicz M, Briles DE, Cook J, Paton JC (2007) Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 75(1):350-357. doi: 10.1128/IAI.01103-06
130. Hakenbeck R, Madhour A, Denapaite D, Bruckner R (2009) Versatility of choline metabolism and choline-binding proteins in Streptococcus pneumoniae and commensal streptococci. FEMS Microbiol Rev 33(3):572-586
131. Yother J, White JM (1994) Novel surface attachment mechanism of the Streptococcus pneumoniae protein PspA. J Bacteriol 176(10):2976-2985
132. Ramos-Sevillano E, Moscoso M, Garcia P, Garcia E, Yuste J (2011) Nasopharyngeal colonization and Invasive disease are enhanced by the cell wall hydrolases LytB and LytC of Streptococcus pneumoniae. PLoS ONE 6(8):e23626. doi: 10.1371/journal.pone.0023626 (pii: PONE-D-11-09880)
133. Wizemann TM, Heinrichs JH, Adamou JE, Erwin AL, Kunsch C, Choi GH, Barash SC, Rosen CA, Masure HR, Tuomanen E, Gayle A, Brewah YA, Walsh W, Barren P, Lathigra R, Hanson M, Langermann S, Johnson S, Koenig S (2001) Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 69(3):1593-1598. doi: 10.1128/IAI.69.3.1593-1598.2001
134. Giefing C, Meinke AL, Hanner M, Henics T, Bui MD, Gelbmann D, Lundberg U, Senn BM, Schunn M, Habel A, Henriques-Normark B, Ortqvist A, Kalin M, von Gabain A, Nagy E (2008) Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 205(1):117-131
135. Sham LT, Tsui HC, Land AD, Barendt SM, Winkler ME (2012) Recent advances in pneumococcal peptidoglycan biosynthesis suggest new vaccine and antimicrobial targets. Curr Opin Microbiol 15(2):194-203. doi: 10.1016/j.mib.2011.12.013
136. Beilharz K, Novakova L, Fadda D, Branny P, Massidda O, Veening JW (2012) Control of cell division in Streptococcus pneumoniae by the conserved Ser/Thr protein kinase StkP. Proc Natl Acad Sci USA 109(15):E905-E913. doi: 10.1073/pnas.1119172109
137. Mahdi LK, Wang H, Van der Hoek MB, Paton JC, Ogunniyi AD (2012) Identification of a novel pneumococcal vaccine antigen preferentially expressed during meningitis in mice. J Clin Invest 122(6):2208-2220. doi: 10.1172/JCI45850
138. Malley R, Lipsitch M, Stack A, Saladino R, Fleisher G, Pelton S, Thompson C, Briles D, Anderson P (2001) Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun 69(8):4870-4873. doi: 10.1128/IAI.69.8. 4870-4873.2001
139. Malley R, Morse SC, Leite LC, Areas AP, Ho PL, Kubrusly FS, Almeida IC, Anderson P (2004) Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect Immun 72(7):4290-4292
140. Malley R, Srivastava A, Lipsitch M, Thompson CM, Watkins C, Tzianabos A, Anderson PW (2006) Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun 74(4):2187-2195. doi: 10.1128/IAI.74.4.2187-2195.2006
141. Basset A, Thompson CM, Hollingshead SK, Briles DE, Ades EW, Lipsitch M, Malley R (2007) Antibody-independent, CD4 + T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun 75(11):5460-5464. doi: 10.1128/IAI.00773-07
142. Lu YJ, Forte S, Thompson CM, Anderson PW, Malley R (2009) Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun 77(5):2076-2083. doi: 10.1128/IAI.01554-08
143. Lu YJ, Yadav P, Clements JD, Forte S, Srivastava A, Thompson CM, Seid R, Look J, Alderson M, Tate A, Maisonneuve JF, Robertson G, Anderson PW, Malley R (2010) Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol 17(6):1005-1012. doi: 10.1128/CVI.00036-10
144. Lu YJ, Leite L, Goncalves VM, Dias Wde O, Liberman C, Fratelli F, Alderson M, Tate A, Maisonneuve JF, Robertson G, Graca R, Sayeed S, Thompson CM, Anderson P, Malley R (2010) GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 28(47):7468-7475. doi: 10.1016/j.vaccine.2010.09.031
145. WHO (2008) Target product profile (TPP) for the advance market commitment (AMC) for pneumococcal conjugate vaccines. 2012 (02/10/2012)
146. Moffitt KL, Yadav P, Weinberger DM, Anderson PW, Malley R (2012) Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine. Vaccine 30(29):4316-4322. doi: 10.1016/j.vaccine.2012.01.034
147. Li Y, Wang S, Scarpellini G, Gunn B, Xin W, Wanda SY, Roland KL, Curtiss R 3rd (2009) Evaluation of new generation Salmonella enterica serovar Typhimurium vaccines with regulated delayed attenuation to induce immune responses against PspA. Proc Natl Acad Sci USA 106(2):593-598. doi: 10.1073/pnas.0811697106
148. Wang S, Li Y, Shi H, Scarpellini G, Torres-Escobar A, Roland KL, Curtiss R 3rd (2010) Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect Immun 78(7):3258-3271. doi: 10.1128/IAI.00176-10
149. Xin W, Wanda SY, Li Y, Wang S, Mo H, Curtiss R 3rd (2008) Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis. Infect Immun 76(7):3241-3254. doi: 10.1128/IAI.01623-07
150. Wang S, Li Y, Scarpellini G, Kong W, Shi H, Baek CH, Gunn B, Wanda SY, Roland KL, Zhang X, Senechal-Willis P, Curtiss R 3rd (2010) Salmonella vaccine vectors displaying delayed antigen synthesis in vivo to enhance immunogenicity. Infect Immun 78(9):3969-3980. doi: 10.1128/IAI.00444-10
151. Xin W, Li Y, Mo H, Roland KL, Curtiss R 3rd (2009) PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun 77(10):4518-4528. doi: 10.1128/IAI.00486-09
152. Xin W, Wanda SY, Zhang X, Santander J, Scarpellini G, Ellis K, Alamuri P, Curtiss R 3rd (2012) The Asd + -DadB + dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated salmonella vaccine. Infect Immun 80(10):3621-3633. doi: 10.1128/IAI.00620-12
153. Shi H, Santander J, Brenneman KE, Wanda SY, Wang S, Senechal P, Sun W, Roland KL, Curtiss R (2010) Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen. PLoS ONE 5(6):e11142. doi: 10.1371/journal.pone.0011142
154. Oliveira ML, Monedero V, Miyaji EN, Leite LC, Lee Ho P, Perez-Martinez G (2003) Expression of Streptococcus pneumoniae antigens, PsaA (pneumococcal surface antigen A) and PspA (pneumococcal surface protein A) by Lactobacillus casei. FEMS Microbiol Lett 227(1):25-31
155. Oliveira ML, Areas AP, Campos IB, Monedero V, Perez-Martinez G, Miyaji EN, Leite LC, Aires KA, Lee Ho P (2006) Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect Institut Pasteur 8(4):1016-1024. doi: 10.1016/j.micinf.2005.10.020
156. Hernani Mde L, Ferreira PC, Ferreira DM, Miyaji EN, Ho PL, Oliveira ML (2011) Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal nasopharyngeal colonization in mice. FEMS Immunol Med Microbiol 62(3):263-272. doi: 10.1111/j.1574-695X.2011.00809.x
157. Hanniffy SB, Carter AT, Hitchin E, Wells JM (2007) Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis 195(2):185-193. doi: 10.1086/509807
158. Campos IB, Darrieux M, Ferreira DM, Miyaji EN, Silva DA, Areas AP, Aires KA, Leite LC, Ho PL, Oliveira ML (2008) Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge. Microbes Infect/Institut Pasteur 10(5):481-488. doi: 10.1016/j.micinf.2008.01.007
159. Ferreira DM, Darrieux M, Silva DA, Leite LC, Ferreira JM Jr, Ho PL, Miyaji EN, Oliveira ML (2009) Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol 16(5):636-645. doi: 10.1128/CVI.00395-08
160. Medina M, Villena J, Vintini E, Hebert EM, Raya R, Alvarez S (2008) Nasal immunization with Lactococcus lactis expressing the pneumococcal protective protein A induces protective immunity in mice. Infect Immun 76(6):2696-2705. doi: 10.1128/IAI.00119-08
161. Ferreira DM, Darrieux M, Oliveira ML, Leite LC, Miyaji EN (2008) Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production. Clin Vaccine Immunol 15(3):499-505
162. Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW (2001) Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 69(11):6718-6724. doi: 10.1128/IAI.69.11.6718-6724.2001
163. Oliveira ML, Miyaji EN, Ferreira DM, Moreno AT, Ferreira PC, Lima FA, Santos FL, Sakauchi MA, Takata CS, Higashi HG, Raw I, Kubrusly FS, Ho PL (2010) Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS ONE 5(5):e10863. doi: 10.1371/journal.pone.0010863
164. Lima FA, Ferreira DM, Moreno AT, Ferreira PC, Palma GM, Ferreira JM Jr, Raw I, Miyaji EN, Ho PL, Oliveira ML (2012) Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with streptococcus pneumoniae in mice. Clin Vaccine Immunol 19(9):1382-1392. doi: 10.1128/CVI.00171-12
165. Briles DE, Hollingshead SK, King J, Swift A, Braun PA, Park MK, Ferguson LM, Nahm MH, Nabors GS (2000) Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182(6):1694-1701
166. Nabors GS, Braun PA, Herrmann DJ, Heise ML, Pyle DJ, Gravenstein S, Schilling M, Ferguson LM, Hollingshead SK, Briles DE, Becker RS (2000) Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18(17):1743-1754
167. Schmid P, Selak S, Keller M, Luhan B, Magyarics Z, Seidel S, Schlick P, Reinisch C, Lingnau K, Nagy E, Grubeck-Loebenstein B (2011) Th17/Th1 biased immunity to the pneumococcal proteins PcsB, StkP and PsaA in adults of different age. Vaccine 29(23):3982-3989. doi: 10.1016/j.vaccine.2011.03.081
168. Seiberling M, Bologa M, Brookes R, Ochs M, Go K, Neveu D, Kamtchoua T, Lashley P, Yuan T, Gurunathan S (2012) Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults. Vaccine. doi: 10.1016/j.vaccine.2012.10.080
169. Kamtchoua T, Bologa M, Hopfer R, Neveu D, Hu B, Sheng X, Corde N, Pouzet C, Zimmerman G, Gurunathan S (2012) Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine. doi: 10.1016/j.vaccine.2012.11.005
170. Bologa M, Kamtchoua T, Hopfer R, Sheng X, Hicks B, Plevic V, Yuan T, Gurunathan S (2012) Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine. Vaccine. doi: 10.1016/j.vaccine.2012.10.076
171. Ferreira DM, Jambo KC, Gordon SB (2011) Experimental human pneumococcal carriage models for vaccine research. Trends Microbiol 19(9):464-470. doi: 10.1016/j.tim.2011.06.003
172. Wright AK, Ferreira DM, Gritzfeld JF, Wright AD, Armitage K, Jambo KC, Bate E, El Batrawy S, Collins A, Gordon SB (2012) Human nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage. PLoS Pathog 8(4):e1002622. doi: 10.1371/journal.ppat.1002622
173. Gritzfeld JF, Roberts P, Roche L, El Batrawy S, Gordon SB (2011) Comparison between nasopharyngeal swab and nasal wash, using culture and PCR, in the detection of potential respiratory pathogens. BMC Res Notes 4:122. doi: 10.1186/1756-0500-4-122
174. Weiser JN (2010) The pneumococcus: why a commensal misbehaves. J Mol Med (Berl) 88(2):97-102. doi: 10.1007/s00109-009-0557-x
175. Croucher NJ, Harris SR, Fraser C, Quail MA, Burton J, van der Linden M, McGee L, von Gottberg A, Song JH, Ko KS, Pichon B, Baker S, Parry CM, Lambertsen LM, Shahinas D, Pillai DR, Mitchell TJ, Dougan G, Tomasz A, Klugman KP, Parkhill J, Hanage WP, Bentley SD (2011) Rapid pneumococcal evolution in response to clinical interventions. Science 331(6016):430-434. doi: 10.1126/science.1198545